CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 167 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $149,484,045 | -14.1% | 5,431,833 | +5.9% | 0.03% | -9.1% |
| Q2 2023 | $174,109,318 | +15.7% | 5,131,427 | +22.7% | 0.03% | +10.0% |
| Q1 2023 | $150,454,364 | -27.4% | 4,181,611 | -10.0% | 0.03% | -28.6% |
| Q4 2022 | $207,157,438 | +139.2% | 4,647,912 | +50.9% | 0.04% | +133.3% |
| Q3 2022 | $86,600,000 | +13.1% | 3,080,733 | +8.5% | 0.02% | +20.0% |
| Q2 2022 | $76,577,000 | -36.3% | 2,840,383 | -19.5% | 0.02% | -28.6% |
| Q1 2022 | $120,227,000 | +42.3% | 3,529,840 | +61.5% | 0.02% | +50.0% |
| Q4 2021 | $84,468,000 | -28.2% | 2,185,976 | +0.3% | 0.01% | -30.0% |
| Q3 2021 | $117,717,000 | +79.3% | 2,180,352 | +11.1% | 0.02% | +81.8% |
| Q2 2021 | $65,642,000 | +68.7% | 1,962,999 | +3.9% | 0.01% | +57.1% |
| Q1 2021 | $38,907,000 | +2258.0% | 1,888,736 | +1905.0% | 0.01% | – |
| Q4 2020 | $1,650,000 | – | 94,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |